The impact of Cana therapy on the STAT-3 pathway may be attributed to p-AMPK-α upregulation; this notion can be supported by Tsogbadrakh et al.57, who reported that p-AMPK-α played a role in STAT-3 suppression and SOCS-3 upregulation in cisplatin-induced acute kidney injury. Here, SOCS3 is linked to acute kidney injury.